Generic Formulation Products

Finished Dosage Forms - Product List:

Download Brochure

Dr. Reddy’s Laboratories is a leading API supplier, with a presence in over 80 countries and a portfolio of 200+ ANDA filings and approved dossiers. Our offering goes beyond APIs and our global customers have access to high-quality dossiers and finished dosage forms.

Therapy Area

Anti-Diabetic

Cardiovascular

Central Nervous System

Gastro-Intestinal

Others

Anti-Obesity

Immuno Suppressant

Oncology

Oncology / Acromegaly

Dosage Form

Oral

Injection

Injectable

Dossier Status

Available

Filed

Under Development

Therapy Area	Product Name	Strength	Dossier Status
Anti-Diabetic	Linagliptin	5 mg	Filed
Anti-Diabetic	Sitagliptin HCL + Metformin	50 + 500, 50 + 850	Under Development
Anti-Diabetic	Linagliptin + Metformin	2.5 mg/500 mg, 2.5 mg/850 mg, 2.5 mg/1000 mg	Filed
Anti-Diabetic	Sitagliptin HCL	25, 50, 100 mg	Filed
Anti-Diabetic	Sitagliptin Phosphate	25, 50 and 100 mg	Filed
Anti-Diabetic	Sitagliptin Phosphate + Metformin	50 + 500, 50 + 1000 mg	Filed
Anti-Diabetic	Liraglutide	6 mg/ml (3 ml)	Under Development
Anti-Obesity	Liraglutide	6 mg/ml (3 ml)	Under Development
Cardiovascular	Eltrombopag	12.5, 25, 50 and 75 mg	Filed
Cardiovascular	Bempedoic acid Ezetimibe	180 mg/10 mg	Under Development
Cardiovascular	Bempedoic acid	120 mg and 240 mg	Under Development
Cardiovascular	Edoxaban	15 mg, 30 mg and 60 mg	Under Development
Cardiovascular	Tafamidis Meglumine	20 mg	Under Development
Cardiovascular	Apixaban	2.5 mg and 5 mg	Filed
Cardiovascular	Dabigatran	75 mg, 110 mg and 150 mg	Filed
Cardiovascular	Rivaroxaban	10, 15 and 20 mg	Filed
Cardiovascular	Sacubitril/ Valsartan	24/26, 49/51, 97/103 mg	Filed
Cardiovascular	Ticagrelor	60 mg and 90 mg	Filed
Cardiovascular	Treprostinil	1 mg/ml, 2.5 mg/ml, 5 mg/ml and 10 mg/ml (20 ml)	Filed
Cardiovascular	Fondaparinux	2.5 mg/0.5 ml, 5 mg/0.4 ml, 7.5 mg/0.6 ml and 10 mg/0.8 ml	Filed
Central Nervous System	Glatiramer	20 mg and 40 mg	Filed
Central Nervous System	Sugammadex	100 mg/ml (2 ml and 5 ml)	Filed
Central Nervous System	Vigabatrin	USP 500 mg	Filed
Central Nervous System	Edaravone	60 mg/100 ml	Filed
Central Nervous System	Topiramate ER	25, 50, 100 and 200 mg	Filed
Central Nervous System	Carboprost	USP Inj 250 mcg/ml PFS	Filed
Central Nervous System	Colchicine	0.6 mg	Filed
Central Nervous System	Dimethyl Fumarate	120 mg and 240 mg	Under Development
Gastro-Intestinal	Esomeprazole	20 mg and 40 mg	Filed
Gastro-Intestinal	Esomeprazole MG + Naproxen Na	20 mg/375 mg, 20 mg/500 mg	Filed
Gastro-Intestinal	Lansoprazole ODT	15 mg and 30 mg	Filed
Immuno Suppressant	Sirolimus	1 mg and 2 mg	Filed
Immuno Suppressant	Tacrolimus	0.5 mg, 1 mg and 5 mg	Filed
Oncology	Busulfan	6 mg/ml (10 ml)	Filed
Oncology	Abiraterone	250 mg and 500 mg	Filed
Oncology	Imatinib Mesylate	100 mg, 400 mg	Filed
Oncology	Carmustine	100 mg	Filed
Oncology	Venetoclax	10 mg, 50 mg and 100 mg	Filed
Oncology	Sorafenib	200 mg	Filed
Oncology	Midostaurin	25 mg	Filed
Oncology	Sunitinib Malate	12.5 mg, 25 mg, 37.5 mg and 50 mg	Filed
Oncology	Carfilzomib	60 mg	Filed
Oncology	Nintedanib	100 mg and 150 mg	Under Development
Oncology	Pazopanib	200 and 400 mg	Under Development
Oncology	Tofacitinib XR	22 mg	Under Development
Oncology	Cabozantinib	20 mg, 40 mg and 60 mg	Under Development
Oncology	Bendamustine RTD	45 mg/ml (4 ml) and 25 mg/ml (4 ml)	Filed
Oncology	Bortezomib	3.5 mg	Filed
Oncology	Fingolimod	0.5 mg	Filed
Oncology	Nano Paclitaxel	100 mg	Under Development
Oncology	Nilotinib	50, 150 and 200 mg	Under Development
Oncology	Lenvatinib	4 mg and 10 mg	Under Development
Oncology	Enzalutamide	40 mg and 80 mg	Under Development
Oncology	Pazopanib	200 and 400 mg	Under Development
Oncology	Palbociclib	75, 100 and 125 mg	Filed
Oncology	Lenalidomide	2.5, 5, 10, 15, 20, 25 mg	Filed
Oncology	Everolimus	2.5, 5, 7.5, 10 mg	Filed
Oncology	Dasatinib	20, 50, 70, 80, 100 and 140 mg	Filed
Oncology	Pomalidomide	1 mg, 2 mg, 3 mg and 4 mg	Filed
Oncology	Bendamustine	25 and 100 mg	Filed
Oncology	Azacitidine	100 mg	Filed
Oncology	Capecitabine	150 mg, 500 mg	Filed
Oncology	Plerixafor	20 mg/ml (1.2 ml)	Filed
Oncology	Olaparib	100 mg and 150 mg	Under Development
Oncology	Pemetrexed	100, 500 and 1 gm	Filed
Oncology	Palonosetron	0.075 mg/5 ml, 0.25 mg/ 5 ml	Filed
Oncology	Liposomal Doxorubicin	2 mg/ml (10 ml and 25 ml)	Filed
Oncology	Fulvestrant	50 mg/ml (5 ml)	Filed
Oncology	Eribulin	0.5 mg/ml (2 ml)	Filed
Oncology	Decitabine	50 mg	Filed
Oncology	Cabazitaxel	40 mg/ml (1.5 ml)	Filed
Oncology / Acromegaly	Lanreotide	60 mg/0.2 ml, 90 mg/0.3 ml and 120 mg/0.5 ml	Under Development
Oncology / Acromegaly	Octerotide	10 mg, 20 mg and 30 mg	Under Development
Others	Teriparatide	0.25 mg/ml (2.4 ml)	Filed
Others	Isotretinoin	10 mg, 20 mg, 30 mg and 40 mg	Filed
Others	Valganciclovir	450 mg	Filed
Others	Mesalamine	250 and 500 mg	Under Development
Others	Amphotericin B	50 mg	Under Development
Others	Apremilast	10, 20 and 30 mg	Filed
Others	Posaconazole	100 mg	Filed
Others	Naproxen Sodium	275 mg and 550 mg	Filed
Others	Mesalamine	250 and 500 mg	Under Development
Others	Amphotericin B	50mg	Under Development
Others	Ferric Carboxy Maltose	50 mg/ml	Under Development
Others	Sevelamer Carbonate	800 mg	Filed
Others	Iron Sucrose	100 mg/5 ml, 200 mg/10 ml and 50 mg/2.5 ml	Filed
Others	Thiamine	200 mg/2 ml 25's	Filed
Others	Daptomycin	350 and 500 mg	Filed

Therapy Area	Product Name	Dosage Form	EU Approval Status	US Approval Status
Immuno Suppressant	Fingolimod 0.5 mg		Approved	Approved
Immuno Suppressant	Tacrolimus Capsules, 0.5 mg, 1 mg and 5 mg		NA	Approved
Immuno Suppressant	Sirolimus 1 mg and 2 mg		NA	Approved
Oncology	Doxorubicin Hydrochloride Liposome Injection, 20 mg/10 ml (2 mg/ml) and 50 mg/25 ml (2 mg/ml) Single-dose Vials	Injection	Under review	Approved
Oncology	Imatinib Mesylate Tablets 100/400 mg		NA	Approved
Oncology	Imatinib Mesylate Capsules 50/100/400 mg		Approved	NA
Oncology	Docetaxel Injection Concentrate and 80 mg/4 ml	Injection	Approved	Approved
Oncology	Bendamustine HCl Concentrate for Solution for Infusion 180 mg 4 ml		Approved	NA
Oncology	Bendamustine Hydrochloride Injection 25 mg/Vial and 100 mg/Vial	Injection	NA	Tentative Approved
Oncology	Capecitabine Tablets 500 mg		Approved	Approved
Oncology	Capecitabine Tablets 150 mg	Oral	NA	Approved
Oncology	Fulvestrant Injection 250 mg/5 ml (50 mg/ml)	Injection	Approved	Approved
Oncology	Everolimus 2.5mg, 5mg & 10mg		Approved	NA
Oncology	Dasatinib 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, 140 mg Film tablet		Under review	Tentative Approved
Oncology	Bortezomib For Injection 3.5 mg/vial	Injection	Approved	Approved
Oncology	Decitabine for Injection 50 mglVial	Injection	NA	Approved
Oncology	Azacitidine for Inj 100 mg/vial	Injection	Approved	Approved
Oncology	Lenalidomide Capsules 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg and 25 mg		NA	Approved (2.5, 20 mg) Tentative approved (Other SKUs)
Oncology	Pemetrexed, 100 mg, 500 mg, powder for concentrate for solution for infusion (Disodium Amorphous)		Approved	Tentative Approved
Oncology	Pemetrexed for Injection 100 mg/vial, 500 mg/vial, 1g/vial	Injection	NA	Tentative Approved
Oncology	Pomalidomide Capsules 1 mg, 2 mg, 3 mg and 4 mg		NA	Tentative Approved
Oncology	Carfilzomib for Injection 60 mg/vial	Injection	NA	Approved
Oncology	Palbociclib Capsules, 75 mg, 100 mg and 125 mg		NA	Tentative Approved
Oncology	Abiraterone Acetate Tablets 250 mg		NA	Approved
Oncology	Melphalan Hydrochloride for Injection, 50 mg Single-Dose Vial	Injection	NA	Approved
Oncology	Cabazitaxel Injection 60 mg/1.5 ml	Injection	Approved	Approved
Oncology	Sunitinib Malate	Oral	NA	Approved

Products under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act and not for commercial sale.

Product Capabilities

Research and Development	Manufacturing Facilities	Nich Product Opportunities	Vertical Integration
4 State-of-the-art R&D centres in India, U.K., U.S., and Netherlands 1200+ research scientists working on various projects	11 formulations manufacturing facilities	Peptides, Prostaglandins, HPAPIs, Innovative drug delivery, Novel dosage forms, Complex Injectables	More than 60% of our formulations are backward integrated with our In- house API

Our 11 formulations manufacturing facilities that are operated in accordance with cGMP (ICH Q7a) and regularly inspected/audited by international regulatory authorities and customers (USFDA, MHRA, EMA, PMDA, TGA, SAHPRA, ANVISA, Russian MoH, CFDA, COFEPRIS and Health Canada).

Dr. Reddy's has an expertise of developing and manufacturing various dosage forms:

Oral Solids	Injectables	Novel Dosage Forms
Tablets, Chewable tablets, Orodispersible	Lyophilized product and Liquid solution	Emulsions, Suspensions, Microspheres Liposomes tablets, Capsules, soft gel capsules Pellets a and Nanoparticles

Highly experienced and integrated technical team to support from filing-to-launch.
Highly experienced technical and global regulatory teams with experience of 350+ Filings and 150+ approvals across B2B markets.

Regulatory services	Tech Transfer support	Bio Study design support
Team of regulatory experts	Complete knowledge transfer	Clinical pharmacokinetic team available
Support filing activities	Support local manufacturing	Design bio study protocol
Across multiple countries of interest

Global Presence

Meet with our product experts in one-on-one virtual sessions

Our experts will answer your questions, provide advice, and help you understand our product better

Set Up a Meeting

Disclaimer

No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.